STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

30(h) of the Investment Company Act of 1940

#### UNITED THERAPEUTICS Corp

Form 4

September 26, 2014

### FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

OMB 3235-0287 Number:

January 31, Expires: 2005

Estimated average burden hours per

response... 0.5

Check this box if no longer subject to Section 16. Form 4 or

**SECURITIES** Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue.

1(b).

Form 5

obligations

(Print or Type Responses)

See Instruction

1. Name and A	2. Issuer Name <b>and</b> Ticker or Trading Symbol UNITED THERAPEUTICS Corp [UTHR]					5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)					
	(First) ED THERAPEU' TION, 1040 SPI		3. Date of Earliest Transaction (Month/Day/Year) 09/25/2014					X Director 10% Owner X Officer (give title Other (specify below) CEO			
	(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person					
SILVER SPRING, MD 20910 — Form filed by More than One Reporting  Person								eporting			
(City)	(State)	(State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Dat (Month/Day/Year)	Execution any	med on Date, if Day/Year)	n Date, if Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code V	Amount	or (D)	Price	(Instr. 3 and 4)			
Common Stock	09/25/2014			M(1)	4,115	A	\$ 34.56 (2)	4,255	D		
Common Stock	09/25/2014			S <u>(1)</u>	2,900	D	\$ 133 (3)	1,355	D		
Common Stock	09/25/2014			S <u>(1)</u>	1,215	D	\$ 133.6 (4)	140	D		
Common								166	I	By Spouse	

Stock

Common Stock 533,094.05 I By Trusts

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	Transaction Derivative Code Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	\$ 34.56 (2)	09/25/2014		M <u>(1)</u>		4,115	12/30/2005	12/30/2015	Common Stock	4,115

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
coporting of the randomization	Director	10% Owner	Officer	Other		
ROTHBLATT MARTINE A						
C/O UNITED THERAPEUTICS CORPORATION	X		CEO			
1040 SPRING STREET	Λ		CEO			
SILVER SPRING, MD 20910						

# **Signatures**

/s/ John S. Hess, Jr. under Power of
Attorney

\*\*Signature of Reporting Person

Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.

Reporting Owners 2

### Edgar Filing: UNITED THERAPEUTICS Corp - Form 4

- (2) Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009.
  - This transaction was executed in multiple trades at prices ranging from \$132.50 to \$133.24. The price reported above reflects the
- (3) weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  - This transaction was executed in multiple trades at prices ranging from \$133.545 to \$133.64. The price reported above reflects the
- (4) weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.